Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Keytruda in dMMR/POLE-EDM Uterine Cancer
NCT04262089Phase 1Completed
- Sponsor
- University Medical Center Groningen
- Start
- Nov 2020
- Primary completion
- Apr 2023
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of pembrolizumab in uterine cancer (2 cohorts), sponsored by University Medical Center Groningen. Primary endpoints: Pathologic response (necrosis/viable tumor cells), Pathologic response (Degree of immune infiltration) and 1 more. Started Nov 2020; status: completed.
02
Drugs
03
Conditions
uterine cancer
Beyond the preview
Go deeper on NCT04262089.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04262089.